| 周期 | 已完成事件 | 价格覆盖率 | 胜率 | 超额收益中位数 | 超额收益平均值 | 最差超额收益 |
|---|---|---|---|---|---|---|
| 5D | 4小样本 | 100.0% (4/4) | 50.0% (2/4) | +0.8% | +0.7% | -1.3% |
| 20D | 4小样本 | 100.0% (4/4) | 50.0% (2/4) | -0.5% | +0.7% | -3.7% |
| 60D | 4小样本 | 100.0% (4/4) | 0.0% (0/4) | -7.5% | -9.1% | -19.1% |
| 120D | 4小样本 | 100.0% (4/4) | 0.0% (0/4) | -21.3% | -22.4% | -38.1% |
公司研究
Hikma Pharmaceuticals PLC
HIK.L · 英国 · 医疗保健 · Drug Manufacturers—Specialty & Generic
内部人信号
内部人活动分数：67.8 / 100
6 位内部人 · 8 个买入事件 · 净买入 €471k
欧洲 #102 · 英国 #31
为什么有这个信号？
评分构成
每条进度条表示其对当前分数的贡献；权重和公式未改变。
聚集度+35.0 / 35
不同内部人是否在相近时间买入
买入规模+21.2 / 25
买入金额相对公司规模和流动性的大小
角色+20.0 / 20
参与买入的内部人职位权重
近期性+1.7 / 10
买入距离当前快照日期有多近
确信度+10.0 / 10
买入相对其他交易的清晰程度
哪些因素限制了当前分数？
- ⚠ 买入活动正在变得不够近期
- ✓ 买方广度较强 · 至少 4 位不同申报人
- ✓ 高级管理层角色 · ceo/chair参与
角色贡献按现有欧洲模型的反向角色输入计算。
买入集中度
50%
最大买方：Victoria Hull · 199k GBP
合资格买入交易行总额（毛额）：397k GBP
顶部的 € 合计为筛选的净买入；本模块使用合资格买入交易行的原币毛额，所以数值可能不同。当前“15 天买方广度”输入反映不同买方数量；金额集中度在此单独披露。
该数值是当前欧洲筛选规则下的排序，不是上涨概率、收益预测或买入建议。
关键买入报价（申报原币）
| 申报人 | 每单位价格 | 交易日期 |
|---|---|---|
| Susan Ringdal | 15.97 GBP | Sep 21, 2026 |
| Julie Hill | 15.97 GBP | Sep 21, 2026 |
| Victoria Hull | 13.76 GBP | Apr 27, 2026 |
模型细节
聚集度拆解（不改变总分）
- 15 天买方广度（计数）
- 4 位不同申报人
- 峰值时间窗口
- 2026-04-27 至 2026-05-05
- 当前广度输入
- 1.000（4 位及以上封顶）
- 买方独立性
- 尚未计量；关联方字段在各市场不可直接比较
申报记录显示什么？
- 🟢 近期合资格买入
Susan Ringdal · 27k GBP · 单价 15.97 GBP · Sep 21, 2026 - 🟢 合资格买入
Julie Hill · 3k GBP · 单价 15.97 GBP · Sep 21, 2026 - 🟢 管理责任人买入
Victoria Hull · 199k GBP · 单价 13.76 GBP · Apr 27, 2026 - 🟡 其余 5 条合资格交易行，来自 5 份披露
- 🔴 20 条其他交易行未计入自主买入信号，其中 6 条为零价格交易
内部人交易与股价
180 天窗口内共 4 个买入日、8 条买入记录。
每日收盘价 (GBp)有内部人买入的交易日同日有两名及以上内部人买入
标记位于交易当日的收盘价上，表示内部人交易的时间，不代表其成交价格。“此后”比较的是当日收盘价与图中最新收盘价，是这家公司已经发生的情况，不是预测。
如果当时跟着买了
每一行从买入被公开当日或之后的第一个收盘价算起（读者最早能行动的时点），到上图最新收盘价为止。
| 公开日 | 内部人数 | 买这只股票，现在 | 买同交易所中位数股票，现在 | 差额 |
|---|---|---|---|---|
| 2026-04-28 | 1 | 1,178 +17.8% | 1,035 +3.5% | +144 +14.4 pts |
| 2026-05-06 | 3 | 1,151 +15.1% | 1,028 +2.8% | +123 +12.3 pts |
| 2026-08-11 | 1 | 1,005 +0.5% | 975 −2.5% | +30 +3.0 pts |
| 2026-09-22 | 3 | 1,025 +2.5% | 988 −1.2% | +36 +3.6 pts |
4 个披露日中，有 4 个跑赢了同交易所中位数股票。
按收盘价计算，未计交易成本、税费、股息和汇率变动。对照的是同一交易所内本站有价格数据的其他股票的中位数（此处 454 只），不是指数。这是已经发生的情况，不是预测：就本站全部买入而言，典型差额接近于零。
内部人时间轴
4 月 27 日至 5 月 5 日的 9 天内有 4 位内部人买入：职务未归类 3、CEO / 董事长 1。其中 2 位此后再次买入。此后另有 2 位买入。这段买入开始那天收盘 1,386.00，最新收盘 1,646.00（+18.8%）。那一周全欧洲有 203 家公司披露了内部人买入，属于普通的一周（最近 26 周里排第 8）。
点开每一项看它的意思。
●一次买入：点越大，买得越多
每个圆点是一位内部人在某一天的买入。点的面积按金额画：这里金额最大的一笔，点最大。把鼠标停在点上可以看到日期和金额。
▮紫色竖带：几个人在 15 天内都买了
竖带标出买入人数最多的一段：最长 15 天，至少两个人。这里是 4 月 27 日 – 5 月 5 日，共 4 位内部人。只标最强的一段。几个人作出同样的决定，比一个人更难用私人原因解释；但静默期刚结束时内部人常常同时买入，所以要对照下面的灰色周柱一起看。
蓝线：这只股票的股价，这半年 +22.1%
每天的收盘价，从 2026-04-21 的 1,348.00 到 2026-10-07 的 1,646.00。这条线没有刻度，只看高低：点落在线的低处，是低位买的；落在高处，就不是。
虚线：同一交易所的一般股票，这半年 +2.3%
取自同一交易所、本站有价格的另外 491 只股票。每只都从窗口第一天起算涨跌，每天画出正中间那一只。它和蓝线从同一点出发，所以两条线之间的距离就是差距：这只股票 +22.1%，一般股票 +2.3%，领先 19.8 个百分点。它不是指数，也不是同行业之间的比较。
▂灰柱：全欧洲每周有多少家公司披露了买入
柱越高，那一周披露内部人买入的公司越多。紫色那根是上面竖带所在的一周：203 家公司，在最近 26 周里排第 8。如果那一周本来就是高峰，“同时买入”就没有看上去那么特别。
本公司每月买入的内部人数，近 12 个月
311 月
112 月
1 月
2 月
13 月
14 月
35 月
6 月
7 月
18 月
39 月
10 月
深色柱在上图的 180 天窗口之内。
谁在交易
| 内部人 | 职务 | 买入次数 | 卖出次数 | 买入金额 | 首次买入 | 此后股价 | 以往买入 |
|---|---|---|---|---|---|---|---|
| Victoria Hull | CEO / 董事长 | 1 | — | 198.9k GBP | 2026-04-27 | +18.8% | 已到期不足 5 笔 |
| Tobias Hestler | 董事会成员 | 1 | — | 123.6k GBP | 2026-08-10 | −0.2% | 已到期不足 5 笔 |
| Hussein Arkhagha | 职务未归类 | 1 | — | 5.7k GBP | 2026-05-05 | +16.7% | 已到期不足 5 笔 |
| Julie Hill | 职务未归类 | 2 | — | 6.0k GBP | 2026-05-05 | +16.7% | 已到期不足 5 笔 |
| Susan Ringdal | 职务未归类 | 2 | — | 59.8k GBP | 2026-05-05 | +16.7% | 已到期不足 5 笔 |
| Sam Park | 职务未归类 | 1 | — | 3.3k GBP | 2026-09-21 | +2.2% | 已到期不足 5 笔 |
评分细节
排序值 = 100 × Σ（固定权重 × 0–1 规则化输入）
| 因子 | 权重 | 本公司输入 | 分数贡献 |
|---|---|---|---|
| 15 天买方广度（计数） | 35% | 1.000 | 35.0 |
| 合资格买入规模 | 25% | 0.847 | 21.2 |
| 角色信息量（反向） | 20% | 0.000 | 0.0 |
| 近期性 | 10% | 0.165 | 1.7 |
| 买卖确信度 | 10% | 1.000 | 10.0 |
这是当前规则的启发式排序，不是经校准的收益预测。它解释候选之间为什么排序不同；公开申报证据和数据限制见下方。
多空辩论
对这轮买入的两种解读
同一批申报，两种读法。每一条都是本站为该公司保存的事实并附上数字，只有当数字越过固定阈值时才会出现。两边都不是预测，这里也不判定哪一方获胜。
自 2026-10-13 以来，两边的论据没有变化。 全站多空榜和各论据的历史记录 →
证据来自哪里
独立证据没有反对：内部人买入这一组有看多证据（高管本人买入），股价与成交、空头、基本面、公司事件核对过，都没有越过看空阈值。
- 内部人买入本身看多高管本人买入 看空按计划、股息或薪酬买入核对过 7 项，未越过阈值 · 缺 2 项数据
- 股价与成交核对过 2 项，未越过阈值
- 空头核对过 1 项，未越过阈值
- 基本面核对过 1 项，未越过阈值 · 缺 1 项数据
- 公司事件核对过 1 项，未越过阈值
看多理由 · 这轮买入有信息量
- 买方包括首席执行官或董事长，即对公司经营了解最全面的人。本站的分数几乎不因此加分：回测中，高管买入之后的表现并不比其他内部人好。历史记录：8,797 次同类披露之后 60 个交易日，超额收益中位数 −3.1%，与可比较的全部披露（−3.2%）相差不到 1 个百分点。
看空理由 · 应当打折扣
- 8 条买入记录中有 6 条的申报措辞属于股息再投资或以股代息，例如“Acquisition of Ordinary Shares through participation in a DRIP”。这类买入按既定安排或既有权利执行，并非当下作出的决定。
还缺少哪些证据
- 这些买方中没有人拥有 5 次以上已完成的历史买入记录，因此无从衡量其过往准确度。
- 目前只有一个时点的盈利数据（利润率 11%）。盈利和现金流是在上升还是下降，需要把最近两期报告放在一起比较。
- 申报只披露每笔交易的规模，不披露买方原有持股。一笔买入是使其个人持股增加 1% 还是翻倍，无从得知。
核对过但没有越过阈值：12 项，其中 2 项接近阈值
- 两边净买入相当于公司市值的 0.01%。达到 0.10% 计入看多，低于 0.01% 计入看空。 接近阈值
- 看空已公布的净空头头寸合计占股本 1.70%；达到 2% 才计入看空。2026-10-02 时为 1.29%，此后上升 0.41 个百分点。 接近阈值
- 看多15 天内最多有 1 位内部人买入；达到 3 位才计入看多。
- 两边最近 180 天有 6 位内部人买入，此前 180 天为 4 位。至少翻倍且多 2 位才计入看多；此前至少 2 位且不少于本期才计入看空。
- 看空最大买方占买入金额的 50%；达到 80% 才计入看空。
- 看空6 位买方中有 0 位以关联人身份申报；达到半数才计入看空。
- 看空同一 180 天内没有记录到内部人卖出。
- 两边最近一笔买入距今 26 天。不超过 14 天计入看多，达到 90 天计入看空。
- 看空股价六个月变动 +24%（三个月 +1.9%，一个月 +3.1%），现价比 52 周高点低 12%；下跌达到 20% 才计入看空。
- 看空三个月里股价变动 +1.9%，同行业（医疗保健，271 家）中位数变动 −6.3%，领先 8 个百分点；落后达到 20 个百分点才计入看空。
- 看多最近 30 天公司没有公告自有股份交易，也就是没有回购。
- 看空按最近一次抓取的数据，利润率为 11%；为负才计入看空。
多空两栏只整理已保存的事实，不影响内部人分数或排名，也不构成投资建议。
信号历史
67.8 / 100
最新留档分数
↑ +0.9 分相对 2026-09-14 的可比快照（间隔 34 个自然日）
- 已留档快照
- 35
- 起始快照
- 2026-08-26
仅比较当时已发布的评分快照。 这些是每次完整评分完成时保存的原始信号分数；它描述研究排序的变化，不是价格图表或收益表现。
为什么变化？
按可比快照拆解五个评分因子的变化；不是重新计算历史分数。
- 买入规模+0.2 pts
- 近期性+0.8 pts
信号分数历史
纵轴固定为 0–100；横轴按快照日期间隔绘制。
近期留档节点
- 65.8
- 67.4
- 72.3
- 69.5
- 67.8
查看全部留档分数
| 快照日期 | 信号分数 |
|---|---|
| 2026-08-26 | 65.8 |
| 2026-08-27 | 65.8 |
| 2026-08-28 | 69.2 |
| 2026-08-31 | 68.6 |
| 2026-09-01 | 68.5 |
| 2026-09-02 | 68.3 |
| 2026-09-03 | 68.2 |
| 2026-09-04 | 68.1 |
| 2026-09-07 | 67.4 |
| 2026-09-08 | 67.3 |
| 2026-09-09 | 67.2 |
| 2026-09-10 | 67.2 |
| 2026-09-11 | 67.1 |
| 2026-09-14 | 66.9 |
| 2026-09-23 | 74.8 |
| 2026-09-24 | 74.3 |
| 2026-09-25 | 73.7 |
| 2026-09-28 | 72.3 |
| 2026-09-29 | 71.9 |
| 2026-09-30 | 71.5 |
| 2026-10-01 | 71.2 |
| 2026-10-02 | 70.8 |
| 2026-10-03 | 70.8 |
| 2026-10-04 | 70.8 |
| 2026-10-05 | 70.0 |
| 2026-10-06 | 69.7 |
| 2026-10-07 | 69.5 |
| 2026-10-08 | 69.2 |
| 2026-10-09 | 69.0 |
| 2026-10-12 | 68.5 |
| 2026-10-13 | 68.3 |
| 2026-10-14 | 68.2 |
| 2026-10-15 | 68.1 |
| 2026-10-16 | 67.9 |
| 2026-10-18 | 67.8 |
行业背景
- 买入广度
- 6.1% (48 / 792 issuers)
- 行业排名
- #11 / 12
- 7 日广度变化
- -0.4 pp · 对比 2026-10-12（6 天）
- 30 日广度变化
- 历史积累中
这是行业层面的研究背景，不影响 Insider Signal 或排名。
内部人历史结果
内部人申报公开后的历史表现。姓名下方同时显示英文职务解释和原始职称。
- 超额收益 = 股票收益 − 同期 FTSE 100 收益。
- 胜率 = 超额收益为正的已完成事件 ÷ 全部已完成事件。
- 价格覆盖率 = 有效时点行情事件 ÷ 已成熟到该周期的事件。
- 收益从公开日当天或之后的首个共同交易日开始计算。
- 小样本规则：n<5 会透明展示，但不参与评分。
事件以 disclosure 为单位；同一公开日的关联申报可能共享相同收益路径，因此不一定统计独立。本研究增强数据不影响 insider score 或排名。
| 周期 | 已完成事件 | 价格覆盖率 | 胜率 | 超额收益中位数 | 超额收益平均值 | 最差超额收益 |
|---|---|---|---|---|---|---|
| 5D | 4小样本 | 100.0% (4/4) | 100.0% (4/4) | +1.3% | +1.6% | +0.6% |
| 20D | 3小样本 | 100.0% (3/3) | 100.0% (3/3) | +2.9% | +4.0% | +1.5% |
| 60D | 3小样本 | 100.0% (3/3) | 33.3% (1/3) | -10.5% | -5.2% | -12.3% |
| 120D | 2小样本 | 100.0% (2/2) | 0.0% (0/2) | -30.4% | -30.4% | -34.9% |
| 周期 | 已完成事件 | 价格覆盖率 | 胜率 | 超额收益中位数 | 超额收益平均值 | 最差超额收益 |
|---|---|---|---|---|---|---|
| 5D | 4小样本 | 100.0% (4/4) | 100.0% (4/4) | +1.3% | +1.6% | +0.6% |
| 20D | 3小样本 | 100.0% (3/3) | 100.0% (3/3) | +2.9% | +4.0% | +1.5% |
| 60D | 3小样本 | 100.0% (3/3) | 33.3% (1/3) | -10.5% | -5.2% | -12.3% |
| 120D | 2小样本 | 100.0% (2/2) | 0.0% (0/2) | -30.4% | -30.4% | -34.9% |
市场背景
PRICE PERFORMANCE
VOLATILITY & LIQUIDITY
- 波动率
- 29.7%
- Beta
- 0.66
- 日均成交额
- £15.3M
VALUATION
- 市值
- £3.3B
- 市盈率
- 12.0×
FUNDAMENTALS
- 利润率
- 11.3%
- ROE
- 15.4%
- 行业
- Drug Manufacturers - Specialty & Generic
价格截至 07 Oct 2026，来源：OpenBB/yfinance。来自 OpenBB/yfinance（抓取于 07 Oct 2026）：市值、市盈率、利润率、ROE、Beta、行业。不影响分数或排名。
已披露的净空头头寸
- 汇总净空头
- 1.70%
- 最近头寸日期
- 14 Oct 2026
FCA 公布每家发行人的汇总数字（所有已申报头寸之和），不公布持有人名称。 来源: FCA · 读取于 18 Oct 2026
空头披露是外部背景，不影响 insider score、排名或申报资格。
内部人买入价与最新收盘价
最近的收盘价已超过一周，不能代表现价。
内部人买入与市场成交规模
行情历史距页面快照过久，暂不计算比例。
行情覆盖: 507 个已核验交易日 · 最新交易日: 2026-10-07 · 比例状态: 暂不可计算
成交额按收盘价 × 成交股数估算，并统一为货币主单位。仅比较已披露的合资格买入；可能存在披露延迟。合同或计划安排不等于自主买入。比例描述相对成交规模，不代表实际市场成交占比，不影响评分。
最新新闻
没有抓取到这家公司的新闻。
监管申报原文
- 内部人申报公告 · 披露日期 2026-09-22 · 交易日期 2026-09-21
- 内部人申报公告 · 披露日期 2026-08-24 · 交易日期 2026-08-21
- 内部人申报公告 · 披露日期 2026-08-11 · 交易日期 2026-08-10
展开全部 14 份申报
- 内部人申报公告 · 披露日期 2026-09-22 · 交易日期 2026-09-21
- 内部人申报公告 · 披露日期 2026-08-24 · 交易日期 2026-08-21
- 内部人申报公告 · 披露日期 2026-08-11 · 交易日期 2026-08-10
- 内部人申报公告 · 披露日期 2026-06-02 · 交易日期 2026-06-01
- 内部人申报公告 · 披露日期 2026-05-06 · 交易日期 2026-05-05
- 内部人申报公告 · 披露日期 2026-04-28 · 交易日期 2026-04-27
- 内部人申报公告 · 披露日期 2026-04-13 · 交易日期 2026-04-09
- 内部人申报公告 · 披露日期 2026-04-09 · 交易日期 2026-04-07
- 内部人申报公告 · 披露日期 2026-03-11 · 交易日期 2026-03-09
- 内部人申报公告 · 披露日期 2025-12-19 · 交易日期 2025-12-19
- 内部人申报公告 · 披露日期 2025-12-19 · 交易日期 2025-12-19
- 内部人申报公告 · 披露日期 2025-12-15 · 交易日期 2025-12-12
- 内部人申报公告 · 披露日期 2025-11-11 · 交易日期 2025-11-07
- 内部人申报公告 · 披露日期 2025-11-07 · 交易日期 2025-11-07
申报证据
以下为当前排名快照日期向前 365 天的底层国家申报记录。评分仅使用最近 180 天；较早的合资格股票买入保留供审计，但不进入当前分数。每张表保留原始字段并先显示前三行，其余记录可展开核验；其他交易不作为自主买入信号。
不计入评分的交易与分类
19 份合资格买入披露（19 条交易行）
Sep 21, 2026Acquisition of Ordinary Shares through participation in a DRIP.
Susan Ringdal · PDMR
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 · 1684 shares × 15.97 GBP · —
打开申报Sep 21, 2026Acquisition of Ordinary Shares through participation in a DRIP.
Julie Hill · PDMR
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 · 218 shares × 15.97 GBP · —
打开申报Sep 21, 2026Acquisition of Ordinary Shares through participation in a DRIP.
Sam Park · PDMR
Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 · 207 shares × 15.97 GBP · —
打开申报展开全部 16 条剩余申报记录
| 交易日期 | 披露日期 | 申报人 | 职位 | 交易类型 | 标的 | 价格（原币主单位） | 报价币种 | 数量 | 来源 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-10 | 2026-08-11 | Tobias Hestler | Non-Executive Director | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 16.48 GBP | GBP | 7500 | 打开申报 |
| 2026-05-05 | 2026-05-06 | Hussein Arkhagha | PDMR | Acquisition of Ordinary Shares through participation in a DRIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 14.098 GBP | GBP | 407 | 打开申报 |
| 2026-05-05 | 2026-05-06 | Susan Ringdal | PDMR | Acquisition of Ordinary Shares through participation in a DRIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 14.098 GBP | GBP | 2337 | 打开申报 |
| 2026-05-05 | 2026-05-06 | Julie Hill | PDMR | Acquisition of Ordinary Shares through participation in a DRIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 14.098 GBP | GBP | 178 | 打开申报 |
| 2026-04-27 | 2026-04-28 | Victoria Hull | Non-Executive Chair | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 13.76 GBP | GBP | 14455 | 打开申报 |
| 2026-03-09 | 2026-03-11 | Hussein Arkhagha | PDMR | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 12.00 GBP | GBP | 6200 | 打开申报 |
| 2025-12-19 | 2025-12-19 | Mazen Darwazah | Executive Vice Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 14.986 GBP | GBP | 100000 | 打开申报 |
| 2025-11-07 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.41 GBP | GBP | 70000 | 打开申报 |
| 2025-11-07 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.89 GBP | GBP | 60000 | 打开申报 |
| 2025-11-07 | 2025-11-07 | Victoria Hull | Senior Independent Director | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.47 GBP | GBP | 3214 | 打开申报 |
| 2025-11-06 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 16.05 GBP | GBP | 100000 | 打开申报 |
| 2025-11-06 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 16.16 GBP | GBP | 100000 | 打开申报 |
| 2025-11-06 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.92 GBP | GBP | 100000 | 打开申报 |
| 2025-11-06 | 2025-11-11 | Said Darwazah | Executive Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.25 GBP | GBP | 100000 | 打开申报 |
| 2025-11-06 | 2025-11-07 | Mazen Darwazah | Executive Vice Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 15.90 GBP | GBP | 115000 | 打开申报 |
| 2025-11-06 | 2025-11-07 | Mazen Darwazah | Executive Vice Chairman | Purchase of Shares in Hikma Pharmaceuticals PLC | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | 16.07 GBP | GBP | 200000 | 打开申报 |
显示 19 of 19 条原始数据，来自当前 365天研究窗口。 价格与申报金额保留申报币种及其主单位（例如英国 pence 在解析时已换为 GBP）。页面顶部的 € 汇总则单独按 FX 快照规范化，仅用于研究排序，不是交易日换汇金额。
其他已披露交易 · 不计入评分
展开 48 条其他交易
Aug 21, 2026Release of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer & Co. Ltd. Darhold Limited is defined as a Person Closely Associated with the Chief Executive Officer, who is a director and shareholder of Darhold Limited.
Said Darwazah · Chief Executive Officer
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 · 2000000 shares × 0.00 GBP · —
打开申报Aug 21, 2026Grant of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Chief Executive Officer, who is a director and shareholder of Darhold Limited.
Said Darwazah · Chief Executive Officer
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 · 2000000 shares × 0.00 GBP · —
打开申报Aug 21, 2026Release of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer & Co. Ltd. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman and Deputy CEO, MENA, who is a director and shareholder of Darhold Limited.
Mazen Darwazeh · Executive Vice Chairman and Deputy CEO, MENA
Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 · 2000000 shares × 0.00 GBP · —
打开申报展开全部 45 条剩余申报记录
| 交易日期 | 披露日期 | 申报人 | 职位 | 交易类型 | 标的 | 价格（原币主单位） | 报价币种 | 数量 | 来源 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-21 | 2026-08-24 | Mazen Darwazeh | Executive Vice Chairman and Deputy CEO, MENA | Grant of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman and Deputy CEO, MENA, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2000000 | 打开申报 |
| 2026-08-21 | 2026-08-24 | Ali Al-Husry | Non-Executive Director | Release of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer & Co. Ltd. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2000000 | 打开申报 |
| 2026-08-21 | 2026-08-24 | Ali Al-Husry | Non-Executive Director | Grant of a pledge by Darhold Limited over 2,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Jordan Kuwait Bank. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2000000 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Said Darwazah | Chief Executive Officer | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 91812 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Said Darwazah | Chief Executive Officer | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 19761 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Mazen Darwazah | Executive Vice Chairman and Deputy CEO, MENA | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 72763 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Mazen Darwazah | Executive Vice Chairman and Deputy CEO, MENA | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 20650 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Khalid Nabilsi | Deputy CEO, North America and Europe | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 51650 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Khalid Nabilsi | Deputy CEO, North America and Europe | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 22209 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Bassam Kanaan | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 52640 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Bassam Kanaan | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 20982 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Hussein Arkhagha | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 28631 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Hussein Arkhagha | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. All shares were retained. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 12406 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Susan Ringdal | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 26558 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Susan Ringdal | PDMR | Shares acquired from the vesting of conditional awards under the LTIP and EIP. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 11664 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Susan Ringdal | PDMR | All shares sold following the vesting of conditional awards under the LTIP and EIP . | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | 14.49 GBP | GBP | 26558 | 打开申报 |
| 2026-06-01 | 2026-06-02 | Susan Ringdal | PDMR | All shares sold following the vesting of conditional awards under the LTIP and EIP . | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | 14.49 GBP | GBP | 11664 | 打开申报 |
| 2026-04-09 | 2026-04-13 | Julie Hill | PDMR | Shares acquired from the vesting of conditional awards under the LTIP. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 8188 | 打开申报 |
| 2026-04-09 | 2026-04-13 | Julie Hill | PDMR | Shares sold to cover tax following the vesting of conditional awards under the LTIP . | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | 13.09 GBP | GBP | 3121 | 打开申报 |
| 2026-04-09 | 2026-04-13 | Sam Park | PDMR | Shares acquired from the vesting of conditional awards under the LTIP. | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | — | GBP | 19045 | 打开申报 |
| 2026-04-09 | 2026-04-13 | Sam Park | PDMR | Shares sold to cover tax following the vesting of conditional awards under the LTIP . | Description: Ordinary shares of 10 pence each ("Shares") ID Code: GB00B0LCW083 | 13.09 GBP | GBP | 7259 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Said Darwazah | Chief Executive Officer | Grant of awards under the LTIP and DBP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 158336 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Said Darwazah | Chief Executive Officer | Grant of awards under the LTIP and DBP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 28149 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Mazen Darwazah | Executive Vice Chairman and Deputy CEO, MENA | Grant of awards under the LTIP and DBP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 126364 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Mazen Darwazah | Executive Vice Chairman and Deputy CEO, MENA | Grant of awards under the LTIP and DBP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 36135 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Khalid Nabilsi | Deputy CEO, North America and Europe | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 100792 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Hussein Arkhagha | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 59221 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Bassam Kanaan | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 88860 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Susan Ringdal | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 49502 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Julie Hill | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 40043 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Hafrun Fridriksdottir | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 87317 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Sam Park | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 61940 | 打开申报 |
| 2026-04-07 | 2026-04-09 | Sam Park | PDMR | Grant of awards under the LTIP. | Description: Ordinary shares of 10 pence each (Shares) ID Code: GB00B0LCW083 | — | GBP | 23000 | 打开申报 |
| 2025-12-19 | 2025-12-19 | Said Darwazah | Executive Chairman and CEO | Release of a pledge Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman and CEO, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | 打开申报 |
| 2025-12-19 | 2025-12-19 | Said Darwazah | Executive Chairman and CEO | Grant of a pledge by Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Europe Arab Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman and CEO, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | 打开申报 |
| 2025-12-19 | 2025-12-19 | Mazen Darwazah | Executive Vice Chairman | Release of a pledge Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | 打开申报 |
| 2025-12-19 | 2025-12-19 | Mazen Darwazah | Executive Vice Chairman | Grant of a pledge by Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Europe Arab Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | 打开申报 |
| 2025-12-19 | 2025-12-19 | Ali Al-Husry | Non-Executive Director | Release of a pledge Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | 打开申报 |
| 2025-12-19 | 2025-12-19 | Ali Al-Husry | Non-Executive Director | Grant of a pledge by Darhold Limited over 2,500,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Europe Arab Bank. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 2500000 | 打开申报 |
| 2025-12-12 | 2025-12-15 | Said Darwazah | Executive Chairman and CEO | Release of a pledge Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman and CEO, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | 打开申报 |
| 2025-12-12 | 2025-12-15 | Said Darwazah | Executive Chairman and CEO | Grant of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of EFG International Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Chairman and CEO, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | 打开申报 |
| 2025-12-12 | 2025-12-15 | Mazen Darwazah | Executive Vice Chairman | Release of a pledge Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | 打开申报 |
| 2025-12-12 | 2025-12-15 | Mazen Darwazah | Executive Vice Chairman | Grant of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of EFG International Bank. Darhold Limited is defined as a Person Closely Associated with the Executive Vice Chairman, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | 打开申报 |
| 2025-12-12 | 2025-12-15 | Ali Al-Husry | Non-Executive Director | Release of a pledge Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of Bank Julius Baer. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | 打开申报 |
| 2025-12-12 | 2025-12-15 | Ali Al-Husry | Non-Executive Director | Grant of a pledge by Darhold Limited over 1,000,000 Ordinary Shares of 10 pence each in Hikma Pharmaceuticals PLC in favour of EFG International Bank. Darhold Limited is defined as a Person Closely Associated with the Non-Executive Director, who is a director and shareholder of Darhold Limited. | Description: Ordinary shares of 10 pence each ID Code: GB00B0LCW083 | 0.00 GBP | GBP | 1000000 | 打开申报 |
显示 48 of 48 条原始数据，来自当前 365天研究窗口。 价格与申报金额保留申报币种及其主单位（例如英国 pence 在解析时已换为 GBP）。页面顶部的 € 汇总则单独按 FX 快照规范化，仅用于研究排序，不是交易日换汇金额。
快照与身份
- 快照日期
- 2026-10-18
- 代码
- HIK.L
- ISIN
- GB00B0LCW083
- 行业
- 医疗保健
- 细分行业
- Drug Manufacturers—Specialty & Generic
公司 logo 由 Parqet 提供